Hi Bee and All.
Something new to talk about. Finally!
A few points of interest.
Adrian slammed home the point of being a Vendor AND Distributor directly to end user liscences.
This is an indication of CRO setting itself up for maximum profit taking. This sales model is DESIGNED to create maximum sales profits over a long term.
This allows a sales margin of whatever they can do deals on which also allows flexibility for expansion.
The $1.8bn pipelined is just a drop in the water when the annual B2B transaction value is $100bn.
Thats values CRO pipeline at 1.8% share.
It is interesting though, that the 1.8% is not CRO trying to take over more pie, they're taking the pie, crumbling it and forming the roots of the tree. The tree is only 1.8% grown in my opinion.
How much of the remaining tree growth will be CRO?
With V3 releasing next year it will be all systems go in 12 months with recurring revenue from the V2 launch customers starting to materialise.
Also,
Did Adrian almost mention an upcoming corporate relationship but then sort of re-compose?
He seemed very positive. All is well.
Goodluck all, sit tight.
Cirralto Investor Webinar, page-46
Featured News
Add SPX (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $55.24M |
Open | High | Low | Value | Volume |
1.2¢ | 1.3¢ | 1.2¢ | $27.92K | 2.327M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
19 | 14816299 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 1191001 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 14816299 | 0.011 |
19 | 6511465 | 0.010 |
10 | 4292884 | 0.009 |
4 | 10224931 | 0.008 |
3 | 5232562 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 1191001 | 3 |
0.013 | 6633711 | 15 |
0.014 | 8482248 | 22 |
0.015 | 3672316 | 11 |
0.016 | 6251500 | 4 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
SPX (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online